European Commission Approves KEYTRUDA® (pembrolizumab) as Part of a Treatment Regimen for Adults with Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Expressing PD-L1 (CPS >1)

Core Viewpoint - The European Commission has approved Merck's KEYTRUDA® for the treatment of resectable locally advanced head and neck squamous cell carcinoma, marking a significant advancement in cancer therapy [1] Group 1: Approval Details - KEYTRUDA® (pembrolizumab) is approved as a monotherapy for neoadjuvant treatment of locally advanced head and neck squamous cell carcinoma [1] - The treatment will continue as adjuvant therapy in combination with radiation therapy, with or without concomitant cisplatin [1] - Following the combination therapy, KEYTRUDA® will be administered as a monotherapy in adults [1]